1 story in the last 7 days
The latest abcellera news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks abcellera across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
AbCellera, the antibody platform behind two authorized COVID-19 therapies, holds over $650M in liquidity against a roughly $1.6B market cap. The stock trades near $5, down more than 90% from its 2021 high. The author initiated coverage with a Buy rating, calling it an asymmetric, catalyst-driven bet.
Summaries by ByteBrief